Rep. Tim Moore Sells Centene Corporation (NYSE:CNC) Shares

Key Points

• Rep. Tim Moore of North Carolina sold shares of Centene Corporation (NYSE:CNC) valued between $100,001 and $250,000 on August 18, 2025.
• Centene's stock is currently trading around $28.62 with a 12-month low of $25.08 and a high of $77.29.
• Multiple brokerages have recently downgraded Centene's ratings, with Wells Fargo cutting its price target from $72.00 to $30.00.

Representative Tim Moore (R-North Carolina) recently sold shares of Centene Corporation NYSE: CNC. In a filing disclosed on September 03rd, the Representative disclosed that they had sold between $100,001 and $250,000 in Centene stock on August 18th.

Representative Tim Moore also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of UnitedHealth Group NYSE: UNH on 8/15/2025.
• Sold $100,001 - $250,000 in shares of Intel NASDAQ: INTC on 8/13/2025.
• Sold $50,001 - $100,000 in shares of Hyster-Yale NYSE: HY on 8/13/2025.
• Purchased $15,001 - $50,000 in shares of Hyster-Yale NYSE: HY on 8/12/2025.
• Purchased $15,001 - $50,000 in shares of Intel NASDAQ: INTC on 8/11/2025.
• Purchased $15,001 - $50,000 in shares of UnitedHealth Group NYSE: UNH on 8/8/2025.
• Purchased $1,001 - $15,000 in shares of Centene NYSE: CNC on 8/8/2025.
• Purchased $15,001 - $50,000 in shares of Intel NASDAQ: INTC on 8/8/2025.
• Purchased $15,001 - $50,000 in shares of Hyster-Yale NYSE: HY on 8/7/2025.
• Purchased $15,001 - $50,000 in shares of Centene NYSE: CNC on 8/7/2025.

Centene Price Performance

Shares of Centene stock opened at $28.62 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.10. The firm's 50-day simple moving average is $30.30 and its 200-day simple moving average is $49.01. Centene Corporation has a twelve month low of $25.08 and a twelve month high of $77.29. The firm has a market cap of $14.06 billion, a P/E ratio of 7.08, a price-to-earnings-growth ratio of 1.22 and a beta of 0.44.

Centene (NYSE:CNC - Get Free Report) last issued its earnings results on Friday, July 25th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.39). Centene had a net margin of 1.15% and a return on equity of 9.57%. The business had revenue of $48.74 billion for the quarter, compared to analyst estimates of $44.71 billion. During the same quarter last year, the firm posted $2.42 earnings per share. Centene's revenue was up 22.4% on a year-over-year basis. Centene has set its FY 2025 guidance at 1.750-1.750 EPS. As a group, research analysts expect that Centene Corporation will post 6.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Centene

Large investors have recently modified their holdings of the stock. Captrust Financial Advisors lifted its position in shares of Centene by 55.6% during the fourth quarter. Captrust Financial Advisors now owns 45,103 shares of the company's stock worth $2,732,000 after purchasing an additional 16,108 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Centene by 32.3% during the first quarter. Farther Finance Advisors LLC now owns 6,333 shares of the company's stock worth $383,000 after purchasing an additional 1,546 shares in the last quarter. AXS Investments LLC bought a new stake in shares of Centene during the first quarter worth approximately $1,458,000. Envestnet Asset Management Inc. lifted its holdings in Centene by 30.0% in the first quarter. Envestnet Asset Management Inc. now owns 708,717 shares of the company's stock valued at $43,026,000 after buying an additional 163,462 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Centene by 41.4% in the fourth quarter. BNP Paribas Financial Markets now owns 925,150 shares of the company's stock valued at $56,046,000 after buying an additional 270,899 shares during the period. 93.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on CNC. Wells Fargo & Company downgraded shares of Centene from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $72.00 to $30.00 in a report on Wednesday, July 23rd. UBS Group cut their price target on shares of Centene from $45.00 to $31.00 and set a "neutral" rating for the company in a report on Monday, July 28th. Robert W. Baird cut their price target on shares of Centene from $68.00 to $28.00 and set a "neutral" rating for the company in a report on Friday, July 25th. Bank of America downgraded shares of Centene from a "neutral" rating to an "underperform" rating and cut their price target for the company from $52.00 to $30.00 in a report on Wednesday, July 16th. Finally, JPMorgan Chase & Co. cut their price target on shares of Centene from $48.00 to $30.00 and set a "neutral" rating for the company in a report on Tuesday, July 29th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $41.40.

Insider Activity at Centene

In other Centene news, CEO Sarah London acquired 19,230 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $25.50 per share, for a total transaction of $490,365.00. Following the completion of the acquisition, the chief executive officer directly owned 845,275 shares of the company's stock, valued at approximately $21,554,512.50. This represents a 2.33% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Theodore R. Samuels II acquired 9,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was acquired at an average price of $27.62 per share, for a total transaction of $248,580.00. Following the completion of the acquisition, the director directly owned 32,000 shares of the company's stock, valued at $883,840. This trade represents a 39.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.36% of the company's stock.

About Representative Moore

Timothy K. Moore (Republican Party) is a member of the U.S. House, representing North Carolina's 14th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Moore (Republican Party) ran for election to the U.S. House to represent North Carolina's 14th Congressional District. He won in the general election on November 5, 2024. Moore served as speaker of the House from 2015 to 2025. Timothy Moore earned his B.A. from the University of North Carolina-Chapel Hill in 1992 and his J.D. from the Oklahoma City University School of Law in 1995. His professional experience includes working as an attorney.

About Centene

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.